Short term statin treatment improves survival and differentially regulates macrophage-mediated responses to staphylococcus aureus

Current Pharmaceutical Biotechnology

Volumn 14, Issue 2, 2013, Pages 233-241

  Burns, Erin M ^a   Smelser, Lisa K ^a   Then, Jenny E ^a   Stankiewicz, Traci E ^a   Kushdilian, Michael ^a   Mcdowell, Susan A ^a   Bruns, Heather A ^a  

^a BALL STATE UNIVERSITY   (United States)

Author keywords

Complement; Inflammation; Macrophage; Membrane vesicle; Sepsis; Simvastatin; Staphylococcus aureus

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LOW DRUG DOSE; MACROPHAGE; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; PROTEIN EXPRESSION; RAT; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE;

EID: 84875299001     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920113805219395     Document Type: Article

References (40)

1. Gasque, P. Complement: a unique innate immune sensor for danger signals. Mol. Immunol., 2004, 41(11), 1089-1098.
2. Stearns-Kurosawa, D.J.; Osuchowski, M.F.; Valentine, C.; Kurosawa, S.; Remick, D.G. The pathogenesis of sepsis. Annu. Rev. Pathol., 2011, 6, 19-48.
3. Burnier, L.; Fontana, P.; Kwak, B.R.; Angelillo-Scherrer, A. Cellderived microparticles in haemostasis and vascular medicine. Thromb. Haemost., 2009, 101(3), 439-4351.
4. Thery, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol., 2009, 9(8), 581-593.
5. Silverman, J.M.; Reiner, N.E. Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol., 2011, 13(1), 1-9.
6. Styers, D.; Sheehan, D.J.; Hogan, P.; Sahm, D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob., 2006, 5, 2.
7. Diekema, D.; Pfaller, M.; Schmitz, F.; Smayevsky, J.; Bell, J.; Jones, R.; Beach, M. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infec. Dis. 2001, 32(Suppl 2), S114-132.
8. Wisplinghoff, H.; Bischoff, T.; Tallent, S.M.; Seifert, H.; Wenzel, R.P.; Edmond, M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis., 2004, 39(3), 309-317.
9. Shorr, A.F.; Tabak, Y.P.; Killian, A.D.; Gupta, V.; Liu, L.Z.; Kollef, M.H. Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit. Care Med., 2006, 34(10), 2588-2595.
10. Fowler, V.G., Jr.; Miro, J.M.; Hoen, B.; Cabell, C.H.; Abrutyn, E.; Rubinstein, E.; Corey, G.R.; Spelman, D.; Bradley, S.F.; Barsic, B.; Pappas, P.A.; Anstrom, K.J.; Wray, D.; Fortes, C.Q.; Anguera, I.; Athan, E.; Jones, P.; van der Meer, J.T.; Elliott, T.S.; Levine, D.P.; Bayer, A.S. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA, 2005, 293(24), 3012-3021.
11. Shorr, A.F. Epidemiology of staphylococcal resistance. Clin. Infect. Dis., 2007, 45 Suppl 3, S171-176.
12. Lowy, F. Staphylococcus aureus infections. N. Eng. J. Med., 1998, 339, 520-532.
13. Smaldone, C.; Brugaletta, S.; Pazzano, V.; Liuzzo, G. Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc. Hematol. Agents Med. Chem., 2009, 7(4), 279-294.
14. Ando, H.; Takamura, T.; Ota, T.; Nagai, Y.; Kobayashi, K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharm. Exper. Therap., 2000, 294(3), 1043-1046.
15. Chaudhry, M.Z.; Wang, J.H.; Blankson, S.; Redmond, H.P. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg. Infec., 2008, 9(2), 183-194.
16. Merx, M.; Liehn, E.; Janssens, U.; Lutticken, R.; Schrader, J.; Hanrath, P.; Weber, C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation, 2004, 109, 2560-2565.
17. Beffa, D.C.; Fischman, A.J.; Fagan, S.P.; Hamrahi, V.F.; Paul, K.W.; Kaneki, M.; Yu, Y.M.; Tompkins, R.G.; Carter, E.A. Simvastatin treatment improves survival in a murine model of burn sepsis: Role of interleukin 6. Burns, 2011, 37(2), 222-226.
18. McDowell, S.A.; Ma, Y.; Kusano, R.; Akinbi, H.T. Simvastatin is Protective During Staphylococcus aureus Pneumonia. Curr. Pharm. Biotechnol., 2011, 12(9), 1455-1462.
19. von Kockritz-Blickwede, M.; Rohde, M.; Oehmcke, S.; Miller, L.S.; Cheung, A.L.; Herwald, H.; Foster, S.; Medina, E. Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am. J. Pathol., 2008, 173(6), 1657-1668.
20. Horn, M.; Knecht, S.; Rushing, F.; Birdsong, J.; Siddall, C.; Johnson, C.; Abraham, T.; Brown, A.; Volk, C.; Gammon, K.; Bishop, D.; McKillip, J.; McDowell, S., Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J. Pharm. Exper. Therap., 2008, 326, 135-143.
21. Newman, T.B.; Hulley, S.B. Carcinogenicity of lipid-lowering drugs. JAMA, 1996, 275(1), 55-60.
22. Jerwood, S.; Cohen, J. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother., 2008, 61, 362-364.
23. Chow, O.A.; von Kockritz-Blickwede, M.; Bright, A.T.; Hensler, M.E.; Zinkernagel, A.S.; Cogen, A.L.; Gallo, R.L.; Monestier, M.; Wang, Y.; Glass, C.K.; Nizet, V. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe, 8(5), 445-454.
24. Djaldetti, M.; Salman, H.; Bergman, M.; Bessler, H. Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. Exp. Mol. Pathol., 2006, 80(2), 160-164.
25. Salman, H.; Bergman, M.; Djaldetti, M.; Bessler, H. Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed. Pharmacother., 2008, 62(1), 41-45.
26. Loike, J.; Shabtai, D.; Neuhut, R.; Malitzky, S.; Lu, E.; Husemann, J.; Goldberg, I.; Silverstein, S., Statin inhibition of Fc receptormediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 2051-2056.
27. Cordle, A.; Koenigsknecht-Talboo, J.; Wilkinson, B.; Limpert, A.; Landreth, G., Mechanisms of statin-mediated inhibition of small Gprotein function. J. Biol. Chem., 2005, 280(40), 34202-34209.
28. Ward, P.A. The harmful role of c5a on innate immunity in sepsis. J. Innate Immun., 2010, 2(5), 439-445.
29. Kuipers, H.F.; Biesta, P.J.; Groothuis, T.A.; Neefjes, J.J.; Mommaas, A.M.; van den Elsen, P.J. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum. Immunol., 2005, 66(6), 653-665.
30. Bhatnagar, S.; Shinagawa, K.; Castellino, F.J.; Schorey, J.S. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood, 2007, 110(9), 3234-3244.
31. Benati, D.; Ferro, M.; Savino, M.T.; Ulivieri, C.; Schiavo, E.; Nuccitelli, A.; Pasini, F.L.; Baldari, C.T. Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. J. Leukoc. Biol., 2010, 87(3), 433-442.
32. Halkes, C.J.; van Dijk, H.; de Jaegere, P.P.; Plokker, H.W.; van Der Helm, Y.; Erkelens, D.W.; Castro Cabezas, M. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler. Thromb. Vasc. Biol., 2001, 2(9), 1526-1530.
33. Muscari, A.; Bastagi, L.; Poggiopollini, G.; Tomassetti, V.; Massarelli, G.; Boni, P.; Puddu, P. Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovasc. Drugs Ther., 2001, 15(5), 453-458.
34. Verseyden, C.; Meijssen, S.; van Dijk, H.; Jansen, H.; Castro Cabezas, M. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J. Lipid Res., 2003, 44(11), 2100-2108.
35. Viedt, C.; Shen, W.; Fei, J.; Kamimura, M.; Hansch, G.M.; Katus, H.A.; Kreuzer, J. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res. Cardiol., 2003, 98(6), 353-361.
36. Fischetti, F.; Carretta, R.; Borotto, G.; Durigutto, P.; Bulla, R.; Meroni, P.L.; Tedesco, F. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin. Exp. Immunol., 2004, 135(2), 186-193.
37. Yoshimura, A.; Inui, K.; Nemoto, T.; Uda, S.; Sugenoya, Y.; Watanabe, S.; Yokota, N.; Taira, T.; Iwasaki, S.; Ideura, T. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J. Am. Soc. Nephrol., 1998, 9(11), 2027-2039.
38. Neale, T.J.; Ojha, P.P.; Exner, M.; Poczewski, H.; Ruger, B.; Witztum, J.L.; Davis, P.; Kerjaschki, D. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J. Clin. Invest., 1994, 94(4), 1577-1584.
39. Lappegard, K.T.; Hvassing, T.; Mollnes, T.E. Statin drugs do not affect serum complement activation in vitro. Scand. J. Immunol., 2004, 60(1-2), 178-183.
40. Stankiewicz, T.E.; Haaning, K.L.; Owens, J.M.; Jordan, A.S.; Gammon, K.; Bruns, H.A.; McDowell, S.A. GTPase activating protein function of p85 facilitates uptake and recycling of the beta1 integrin. Biochem. Biophys. Res. Commun., 2010, 391(1), 443-448.